tirzepatide law firm in west virginia Knoxville ๐ A CDL DUI charge
Description
The baseline utility value for obesity was set at 0.80 quality-adjusted life-years (QALYs)
Pre-filled, no mixing, one-click weekly injection
The primary endpoint was the mean change in HbA1c from baseline to week 52 for tirzepatide relative to insulin lispro (Rosenstock et al., 2023)
When used as monotherapy or with medications that do not independently cause hypoglycemia, tirzepatide has a low intrinsic risk of causing clinically significant hypoglycemia
10.1016/j.jacbts.2018.09.004 35 RegmiA.AiharaE.ChristeM
